Oppenheimer Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.7M | Sell |
126,831
-5,499
| -4% | -$770K | 0.2% | 118 |
|
|
2025
Q4 | $16.2M | Sell |
132,330
-3,672
| -3% | -$446K | 0.2% | 118 |
|
|
2025
Q3 | $15.1M | Buy |
136,002
+6,305
| +5% | +$717K | 0.17% | 145 |
|
|
2025
Q2 | $14.4M | Buy |
129,697
+4,565
| +4% | +$486K | 0.16% | 148 |
|
|
2025
Q1 | $14M | Sell |
125,132
-4,208
| -3% | -$434K | 0.17% | 141 |
|
|
2024
Q4 | $11.9M | Sell |
129,340
-54,832
| -30% | -$4.94M | 0.15% | 163 |
|
|
2024
Q3 | $15.4M | Buy |
184,172
+948
| +0.5% | +$72.3K | 0.19% | 137 |
|
|
2024
Q2 | $12.6M | Buy |
183,224
+31,148
| +20% | +$2.08M | 0.16% | 149 |
|
|
2024
Q1 | $11.1M | Sell |
152,076
-25,311
| -14% | -$1.95M | 0.16% | 154 |
|
|
2023
Q4 | $14.4M | Buy |
177,387
+4,802
| +3% | +$374K | 0.2% | 126 |
|
|
2023
Q3 | $12.9M | Buy |
172,585
+5,798
| +3% | +$446K | 0.2% | 122 |
|
|
2023
Q2 | $12.9M | Sell |
166,787
-14,764
| -8% | -$1.18M | 0.19% | 130 |
|
|
2023
Q1 | $15.1M | Buy |
181,551
+675
| +0.4% | +$55.9K | 0.23% | 104 |
|
|
2022
Q4 | $15.5M | Buy |
180,876
+2,511
| +1% | +$199K | 0.25% | 97 |
|
|
2022
Q3 | $11M | Buy |
178,365
+35,046
| +24% | +$2.21M | 0.19% | 129 |
|
|
2022
Q2 | $8.86M | Buy |
143,319
+628
| +0.4% | +$38.9K | 0.15% | 165 |
|
|
2022
Q1 | $8.48M | Buy |
142,691
+5,613
| +4% | +$359K | 0.12% | 208 |
|
|
2021
Q4 | $9.95M | Buy |
137,078
+32,381
| +31% | +$2.23M | 0.13% | 191 |
|
|
2021
Q3 | $7.31M | Buy |
104,697
+667
| +0.6% | +$46.9K | 0.1% | 226 |
|
|
2021
Q2 | $7.16M | Buy |
104,030
+37,488
| +56% | +$2.5M | 0.1% | 237 |
|
|
2021
Q1 | $4.3M | Buy |
66,542
+3,392
| +5% | +$219K | 0.07% | 318 |
|
|
2020
Q4 | $3.68M | Sell |
63,150
-1,008
| -2% | -$60.8K | 0.06% | 332 |
|
|
2020
Q3 | $4.05M | Sell |
64,158
-11,311
| -15% | -$784K | 0.08% | 285 |
|
|
2020
Q2 | $5.81M | Buy |
75,469
+484
| +0.6% | +$37.1K | 0.12% | 206 |
|
|
2020
Q1 | $5.61M | Buy |
74,985
+47,164
| +170% | +$3.26M | 0.14% | 176 |
|
|
2019
Q4 | $1.81M | Sell |
27,821
-1,485
| -5% | -$96.7K | 0.04% | 444 |
|
|
2019
Q3 | $1.86M | Buy |
29,306
+20,425
| +230% | +$1.34M | 0.04% | 426 |
|
|
2019
Q2 | $599K | Buy |
8,881
+289
| +3% | +$19K | 0.01% | 768 |
|
|
2019
Q1 | $559K | Sell |
8,592
-9,810
| -53% | -$652K | 0.01% | 768 |
|
|
2018
Q4 | $1.15M | Sell |
18,402
-1,652
| -8% | -$115K | 0.03% | 522 |
|
|
2018
Q3 | $1.55M | Buy |
20,054
+11,100
| +124% | +$838K | 0.03% | 491 |
|
|
2018
Q2 | $634K | Buy |
8,954
+444
| +5% | +$31.4K | 0.02% | 727 |
|
|
2018
Q1 | $642K | Buy |
8,510
+1,981
| +30% | +$157K | 0.02% | 717 |
|
|
2017
Q4 | $530K | Hold |
6,529
| – | – | 0.01% | 772 |
|
|
2017
Q3 | $530K | Sell |
6,529
-4,082
| -38% | -$312K | 0.01% | 776 |
|
|
2017
Q2 | $752K | Sell |
10,611
-10,421
| -50% | -$693K | 0.02% | 674 |
|
|
2017
Q1 | $1.43M | Buy |
+21,032
| New | +$1.48M | 0.04% | 451 |
|
Other funds holding GILD
VCM
VPM
Oppenheimer Asset Management's GILD Position: Q1 2026 in Review
Oppenheimer Asset Management reduced its Gilead Sciences (GILD) stake by 4.2% in Q1 2026, selling an estimated $770K and leaving 126,831 shares worth $17.7M. The position accounts for 0.2% of the portfolio, ranked #118.
Oppenheimer Asset Management first reported a position in GILD in Q1 2017 and has held it in 37 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Oppenheimer Asset Management held 126,831 shares of Gilead Sciences worth $17.7M as of Q1 2026.
- Oppenheimer Asset Management sold 5,499 Gilead Sciences shares in Q1 2026, an estimated $770K.
- Gilead Sciences made up 0.2% of Oppenheimer Asset Management's portfolio in Q1 2026, its #118 holding.
- Oppenheimer Asset Management first reported a position in Gilead Sciences in Q1 2017 and has held it in 37 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.